These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 1661268)

  • 21. Effects of anagrelide on megakaryopoiesis and platelet production.
    Thiele J; Kvasnicka HM; Schmitt-Graeff A
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):352-61. PubMed ID: 16810611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of symptomatic patients with essential thrombocythemia: effectiveness of anagrelide.
    Cacciola RR; Cipolla A; Di Francesco E; Giustolisi R; Cacciola E
    Am J Hematol; 2005 Sep; 80(1):81-3. PubMed ID: 16138352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia.
    Petrides PE
    Expert Opin Pharmacother; 2004 Aug; 5(8):1781-98. PubMed ID: 15264993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anagrelide platelet-lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms.
    Espasandin YR; Glembotsky AC; Grodzielski M; Lev PR; Goette NP; Molinas FC; Marta RF; Heller PG
    J Thromb Haemost; 2015 Apr; 13(4):631-42. PubMed ID: 25604267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anagrelide: a new drug for treating thrombocytosis.
    Silverstein MN; Petitt RM; Solberg LA; Fleming JS; Knight RC; Schacter LP
    N Engl J Med; 1988 May; 318(20):1292-4. PubMed ID: 3362187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of anagrelide on platelet factor 4 and vascular endothelial growth factor levels in patients with essential thrombocythemia.
    Cacciola RR; Francesco ED; Giustolisi R; Cacciola E
    Br J Haematol; 2004 Sep; 126(6):885-6. PubMed ID: 15352995
    [No Abstract]   [Full Text] [Related]  

  • 27. Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia.
    Jurgens DJ; Moreno-Aspitia A; Tefferi A
    Haematologica; 2004 Nov; 89(11):1394-5. PubMed ID: 15531464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures.
    Wang G; Franklin R; Hong Y; Erusalimsky JD
    Br J Pharmacol; 2005 Oct; 146(3):324-32. PubMed ID: 16041400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hematologic Malignancies/Pediatric Malignancies. II. Treatment of Essential Thrombocythemia--The Role of Anagrelide].
    Kitanaka A; Shimoda K
    Gan To Kagaku Ryoho; 2016 May; 43(5):535-8. PubMed ID: 27344681
    [No Abstract]   [Full Text] [Related]  

  • 30. A long-term study of young patients with essential thrombocythemia treated with anagrelide.
    Mazzucconi MG; Redi R; Bernasconi S; Bizzoni L; Dragoni F; Latagliata R; Santoro C; Mandelli F
    Haematologica; 2004 Nov; 89(11):1306-13. PubMed ID: 15531452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients].
    Burkhard R; Adam H; Widmer L; Honegger HP
    Schweiz Med Wochenschr; 1998 Nov; 128(46):1808-12. PubMed ID: 9857387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of platelet counts in the management of essential thrombocythemia: experience with anagrelide.
    Griesshammer M
    Expert Rev Hematol; 2009 Jun; 2(3):227-36. PubMed ID: 21082965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Anagrelide in the treatment of thrombocythemia essential (ET)].
    Mazur G; Wróbel T; Podolak-Dawidziak M; Kuliszkiewicz-Janus M; Potoczek S; Nosol J; Kuliczkowski K
    Pol Arch Med Wewn; 2004 Dec; 112(6):1445-50. PubMed ID: 15962609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Anagrelide for treatment of patients with essential thrombocythaemia].
    Boban A; Sertić D; Radman I; Zupancić-Salek S; Zadro R; Labar B
    Lijec Vjesn; 2008; 130(5-6):141-5. PubMed ID: 18792562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anagrelide, a selective thrombocytopenic agent.
    Oertel MD
    Am J Health Syst Pharm; 1998 Oct; 55(19):1979-86. PubMed ID: 9784784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of essential thrombocythemia with anagrelide.
    Silverstein MN; Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):23-5. PubMed ID: 9930554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anagrelide-induced visual hallucinations in a patient with essential thrombocythemia.
    Swords R; Fay M; O'Donnell R; Murphy PT
    Eur J Haematol; 2004 Sep; 73(3):223-4. PubMed ID: 15287922
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment of essential thrombocythemia with anagrelide: a ten-year experience].
    Kornblihtt LI; Vassallu PS; Heller P; Molinas FC
    Medicina (B Aires); 2002; 62(3):231-6. PubMed ID: 12150005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Drug-induced interstitial pneumonitis in essential thrombocythemia treated with anagrelide].
    Kajiguchi T; Kamoshita S; Ito T; Yagi M; Kimura T
    Rinsho Ketsueki; 2017; 58(2):119-125. PubMed ID: 28321088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis.
    Mesquita Mdo C; Sol EB; Malarme M; Noubouossie D; Demulder AC
    Clin Ther; 2009 Nov; 31(11):2559-64. PubMed ID: 20110000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.